ISRCTN83014658已完成未知
An exploratory research study to evaluate the concentration of volatile organic compounds in exhaled breath following use of the logic compact e-cigarette and tobacco flavour pod in healthy males and females who are current daily users of any tobacco and/or non-medicinal electronic nicotine delivery products.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy male or female subject who are current daily users of any tobacco and / or non-medicinal electronic nicotine delivery products., between 19 and 65 years of age, inclusive. Age verification will be performed by checking valid forms of government-issued identification (e.g., passport, driving licence or validate UK card) during Screening.
- •2. Female subject of childbearing potential willing to use 2 effective methods of contraception, i.e., established method of contraception + condom, if applicable (unless of non-childbearing potential or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from the first dose until 1 month after the last dose of IP.
- •3. Female subject of non-childbearing potential. For the purposes of this study, this is defined as the subject being amenorrhoeic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy).
- •4. Female subject with a negative pregnancy test at Screening Visit and before the first dose administration of the IP on Day 1.
- •5. Female subject of post-menopausal status confirmed by demonstrating at Screening Visit that the serum level of the follicle-stimulating hormone (FSH) falls within the respective pathology reference range. In the event a subject's menopausal status has been clearly established (for example, the subject indicates she has been amenorrhoeic for 10 years, confirmed by medical history, etc), but serum FSH levels are not consistent with a postmenopausal status, determination of the subject’s eligibility to be included in the study will be at the Investigator’s discretion following consultation with the Sponsor.
- •6. Male subject willing to use 2 effective methods of contraception, i.e., established method of contraception + condom, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from Day 1 visit until completion of the Follow Up Phone Call.
- •7. Subject with a BMI of = 18.0 or =32.0 kg/m2
- •8. Prior to study start, subjects must be a self-reported current daily user of any tobacco and/or non-medicinal electronic nicotine delivery product (with at least 12 months of consistent use), who are not intending to make a quit attempt, change / alter their tobacco or nicotine usage during the study and up to completion of the post-study telephone follow-up call that can tolerate an e-liquid concentration of up to 18 mg/mL prior to the Screening Visit. This should include conventional cigarette smokers, e-cigarette users, roll-your-own cigarette smokers or dual users (of either conventional cigarette and/or roll-your-own cigarette smokers and e-cigarette users).
- •9. No clinically significant abnormal laboratory test results (in the opinion of the investigator) for serum biochemistry and haematology within 28 days before receiving the first dose administration of the IP.
- •10. Subject with a negative urinary DOA screen (including alcohol) test results, determined within 28 days before the first dose administration of the IP unless there is a documented medical explanation for the positive result other than drugs of abuse (e.g., the subject has been presc
排除标准
- •1. Subject who is a menthol cigarette smoker or menthol e-cigarette user
- •2. Subject who is a snuff or snus tobacco user
- •3. Subject who has any clinically relevant abnormal findings on the physical examination, medical history, lung function tests, 12-lead ECG, or clinical laboratory evaluations, unless deemed not clinically significant by the investigator or their appropriately qualified designee
- •4. Subject who has, or who has had a relevant history of any clinically significant: neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, or haematological conditions and/or other significant medical conditions including, without limitation, those pertaining to COVID-19 that, in the opinion of the Investigator or their appropriately qualified designee, would jeopardise the safety of the subject, safety of anyone involved in the study or impact on the validity of the study results
- •5. Subject who has used prescription or over-the-counter bronchodilator medication (e.g. inhaled or oral ß-adrenergic agonists) to treat a chronic condition within the 12 months prior to Screening visit
- •6. Subject who has received any medications or substances (other than tobacco) which are known to be strong inducers or inhibitors of cytochrome P450 (CYP) and CY2A6 enzymes within 14 days (or 5 half-lives (whichever is longer) prior to Screening
- •7. Subject who has a clinically significant acute illness (e.g., respiratory tract infection) requiring treatment within 4 weeks prior to first dose
- •8. Subject who, prior to enrolment, is planning to quit/reduce their tobacco/nicotine usage during the study and up to completion of the post-study telephone follow-up call. All subjects will be informed that they are free to quit nicotine use and withdraw from the study at any time
- •9. Subject who has had any treatment with smoking cessation medications (e.g., Bupropion, Champix or any nicotine replacement therapies (NRTs)) within 8 weeks of the planned first nicotine dosing occasion
- •10. Subject who is unwilling to trial the study product during their Screening and/or Day 1 Visit
- •11. Female subject who is pregnant or breastfeeding or intending to become pregnant during the course of the study. This will be confirmed with a pregnancy test performed at Screening and before the first product use. and on Admission. Any female subject who becomes pregnant during this study will be withdrawn
- •12. Subject is a current or former employee of the tobacco and vaping industry or is a first-degree relative (parent, sibling, child)
- •13. Subject with a known allergy to the components of the Investigational Products
- •14. Subject who is unable or unwilling to participate in the Day 1 visit
- •15. Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the 30 days before the Day 1 visit (washout period between studies is defined as the period of time elapsed between receiving the last dose of the previous study and receiving the first dose of the next study)
- •16. Subject who, in the opinion of the Investigator, is unsuitable for participation in the study
- •17. A clinically significant history of drug or alcohol ab
研究者
相似试验
已完成
不适用
An explorative and experimental study to assess the feasibility, acceptability and effectiveness of four imagery intervention techniques in the treatment of auditory vocal hallucinationsNL-OMON53589GGZ Eindhoven (Eindhoven)32
尚未招募
不适用
An explorative and experimental study to assess the feasibility, acceptability, and effectiveness of early intervention with light, lifestyle and ImCT therapy in individuals at risk for severe mental illnessNL-OMON53231GGZ Eindhoven (Eindhoven)50
招募中
4 期
Daptomycin in treating patients with cancer having low blood count with fever due to known or suspected serious bacterial infectionsCTRI/2013/03/003477ovartis Healthcare Pvt Ltd100
尚未招募
2 期
Prospective study to explore the impact of the continuous individual nutritional counseling on the body weight loss in post-gastrectomy patientsGastric cancerJPRN-UMIN000033548ara Medical University, Department of Surgery60
招募中
不适用
Prospective exploratory study for evaluating the efficacy of taking ENEVO long term for gastric cancer patients after gastrectomy.gastric cancerJPRN-UMIN000017913Fujita Health University Hospital60